Journal of Clinical and Experimental Investigations

• McCullough PA, Alexander PE, Armstrong R, Arvinte C, Bain AF, Bartlett RP, et al. Multifaceted highly targeted sequential multidrug treatment of early ambulatory high-risk SARS-CoV-2 infection (COVID-19). Rev Cardiovasc Med. 2020; 21: 517-30. doi: 10.31083/j.rcm.2020.04.264.
• Chaves Filho AJMC, Gonçalves F, Mottin M, Andrade CH, Fonseca SNS, Macedo DS. Tetracyclines for COVID-19 neurological and neuropsychiatric manifestations: a valid option to control SARS-CoV-2-associated neuroinflammation? J Neuroimmune Pharmacol. 2021; 16: 213-8. doi: 10.1007/s11481-021-09986-3
• Bernardino ALF, Kaushal D, Philipp MT. The antibiotics doxycycline and minocycline inhibit the inflammatory responses to the Lyme disease spirochete Borrelia burgdorferi. J Infect Dis. 2009; 199: 1379-88. doi: 10.1086/597807
• Yuan B, Yang R, Ma Y, Zhou S, Zhang X, Liu Y. A systematic review of the active saikosaponins and extracts isolated from Radix Bupleuri and their applications. Pharm Biol. 2017; 55: 620-35. doi: 10.1080/13880209.2016.1262433
• Langevitz P, Livneh A, Bank I, Pras M. Benefits and risks of minocycline in rheumatoid arthritis. Drug Saf. 2000; 22: 405-14. doi: 10.2165/00002018-200022050-00007
• Miwa K. Oral minocycline challenge as a potential first line therapy for myalgic encephalomyelitis and long COVID-19 syndrome. Ann Clin Med Case Rep. 2022; V8: 1-4.
• Takayama S, Namiki T, Odaguchi H, Arita R, Hisanaga A, Mitani K, et al. Prevention and recovery of COVID-19 patients with Kampo medicine: review of case reports and ongoing clinical trials. Front Pharmacol. 2021; 12: 656246. doi: 10.3389/fphar.2021.656246

Vancouver

Ohe M, Shida H, Yamamoto J, Seki M, Furuya K. Successful treatment with minocycline and Saiko-keishi-to for COVID-19. J CLIN EXP INVEST. 2023;14(2):em00815. https://doi.org/10.29333/jcei/12999

APA

Ohe, M., Shida, H., Yamamoto, J., Seki, M., & Furuya, K. (2023). Successful treatment with minocycline and Saiko-keishi-to for COVID-19. Journal of Clinical and Experimental Investigations, 14(2), em00815. https://doi.org/10.29333/jcei/12999

AMA

Ohe M, Shida H, Yamamoto J, Seki M, Furuya K. Successful treatment with minocycline and Saiko-keishi-to for COVID-19. J CLIN EXP INVEST. 2023;14(2), em00815. https://doi.org/10.29333/jcei/12999

Chicago

Ohe, Masashi, Haruki Shida, Junya Yamamoto, Masahide Seki, and Ken Furuya. "Successful treatment with minocycline and Saiko-keishi-to for COVID-19". Journal of Clinical and Experimental Investigations 2023 14 no. 2 (2023): em00815. https://doi.org/10.29333/jcei/12999

Harvard

Ohe, M., Shida, H., Yamamoto, J., Seki, M., and Furuya, K. (2023). Successful treatment with minocycline and Saiko-keishi-to for COVID-19. Journal of Clinical and Experimental Investigations, 14(2), em00815. https://doi.org/10.29333/jcei/12999

MLA

Ohe, Masashi et al. "Successful treatment with minocycline and Saiko-keishi-to for COVID-19". Journal of Clinical and Experimental Investigations, vol. 14, no. 2, 2023, em00815. https://doi.org/10.29333/jcei/12999